GoAI
Get started
Centene Corp. logo

Centene Corp.

CNC

NYSEHealthcareMedical - Healthcare Plans

Open in GoAI

Previous close

$65.02

+$0.88 · +1.37%

Aug 21, 3:59 PM ET

CNC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

60

Neutral

Sentiment

64

Bullish

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Industry
Medical - Healthcare Plans
Sector
Healthcare
Headquarters
US
CEO
Sarah London
Listed since
Dec 13, 2001
Employees
61,100

Market position

Day range

Current $65.02

52-week range

Current $65.02

Open
$64.07
Previous close
$64.14
Volume
2.17M
0.4× average
Average volume
5.45M
Average daily volume
Market cap
32.12B USD
Beta
1.11
Market reference 1
50-day average
$64.9708
+0.08% above average
200-day average
$48.707
+33.49% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
21.1B USD
P/E (TTM)
-6.25×
P/B (TTM)
1.42×
P/S (TTM)
0.17×
EV / EBITDA
-4.1×
Earnings yield
-33.02%
Free cash flow yield
21.38%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
16.13%
Operating margin
-2.82%
Net margin
-2.63%
Return on equity
-33.44%
Return on assets
-8.59%
Return on invested capital
-13.41%

Financial health

Debt / equity
0.71×
Current ratio
1.68×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends14%7%1%-6%Gross margin, FY2021: 11.27%Gross margin, FY2022: 11.52%Gross margin, FY2023: 11.24%Gross margin, FY2024: 10.32%Gross margin, FY2025: 12.24%Operating margin, FY2021: 1.42%Operating margin, FY2022: 0.91%Operating margin, FY2023: 1.90%Operating margin, FY2024: 1.95%Operating margin, FY2025: -3.91%Net margin, FY2021: 1.07%Net margin, FY2022: 0.83%Net margin, FY2023: 1.75%Net margin, FY2024: 2.03%Net margin, FY2025: -3.43%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 11.27%. Gross margin FY2022 11.52%. Gross margin FY2023 11.24%. Gross margin FY2024 10.32%. Gross margin FY2025 12.24%. Operating margin FY2021 1.42%. Operating margin FY2022 0.91%. Operating margin FY2023 1.90%. Operating margin FY2024 1.95%. Operating margin FY2025 -3.91%. Net margin FY2021 1.07%. Net margin FY2022 0.83%. Net margin FY2023 1.75%. Net margin FY2024 2.03%. Net margin FY2025 -3.43%.

Income trends

Revenue

194.78B USD+19.44%

Operating income

−7.62B USD−10.79B USD

Net income

−6.67B USD−9.98B USD
Income trends across reported periods215.02B USD134.06B USD53.1B USD−27.86B USDRevenue, FY2021: 125.98B USDRevenue, FY2022: 144.55B USDRevenue, FY2023: 154B USDRevenue, FY2024: 163.07B USDRevenue, FY2025: 194.78B USDOperating income, FY2021: 1.78B USDOperating income, FY2022: 1.32B USDOperating income, FY2023: 2.93B USDOperating income, FY2024: 3.18B USDOperating income, FY2025: −7.62B USDNet income, FY2021: 1.35B USDNet income, FY2022: 1.2B USDNet income, FY2023: 2.7B USDNet income, FY2024: 3.31B USDNet income, FY2025: −6.67B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 125.98B USD. Revenue FY2022 144.55B USD. Revenue FY2023 154B USD. Revenue FY2024 163.07B USD. Revenue FY2025 194.78B USD. Operating income FY2021 1.78B USD. Operating income FY2022 1.32B USD. Operating income FY2023 2.93B USD. Operating income FY2024 3.18B USD. Operating income FY2025 −7.62B USD. Net income FY2021 1.35B USD. Net income FY2022 1.2B USD. Net income FY2023 2.7B USD. Net income FY2024 3.31B USD. Net income FY2025 −6.67B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue194.78B USD163.07B USD154B USD144.55B USD125.98B USD
Cost of goods sold170.94B USD146.24B USD136.68B USD127.89B USD111.78B USD
Gross profit23.83B USD16.83B USD17.32B USD16.66B USD14.2B USD
Selling, general, and administrative13.26B USD12.4B USD12.56B USD11.59B USD9.6B USD
Operating expenses31.45B USD13.65B USD14.39B USD15.34B USD12.42B USD
Interest expense678M USD702M USD725M USD665M USD665M USD
Depreciation and amortization1.28B USD1.24B USD1.29B USD1.43B USD1.34B USD
Operating income−7.62B USD3.18B USD2.93B USD1.32B USD1.78B USD
Net income−6.67B USD3.31B USD2.7B USD1.2B USD1.35B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+48.62%
11 comparable reports
Latest EPS result
2.51
Estimate 1.09 · Beat by 130.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.741.960.19-1.59Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 4, 2025: actual 0.8, estimate 0.44, surprise +81.82%, Beat. Q2 2025, reported Apr 25, 2025: actual 2.9, estimate 2.52, surprise +15.08%, Beat. Q3 2025, reported Jul 25, 2025: actual -0.16, estimate 0.112, surprise -243.37%, Miss. Q4 2025, reported Oct 29, 2025: actual 0.5, estimate -0.145, surprise +445.42%, Beat. Q1 2026, reported Feb 6, 2026: actual -1.19, estimate -1.22, surprise +2.46%, Beat. Q2 2026, reported Apr 28, 2026: actual 3.37, estimate 2.23, surprise +51.12%, Beat. Q3 2026, reported Jul 28, 2026: actual 2.51, estimate 1.09, surprise +130.28%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates55.72B49.55B43.39B37.22BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 4, 2025: actual 40.81B USD, estimate 39.36B USD, surprise +3.67%, Beat. Q2 2025, reported Apr 25, 2025: actual 46.62B USD, estimate 42.76B USD, surprise +9.03%, Beat. Q3 2025, reported Jul 25, 2025: actual 48.74B USD, estimate 44.14B USD, surprise +10.44%, Beat. Q4 2025, reported Oct 29, 2025: actual 49.69B USD, estimate 47.72B USD, surprise +4.12%, Beat. Q1 2026, reported Feb 6, 2026: actual 49.73B USD, estimate 48.41B USD, surprise +2.71%, Beat. Q2 2026, reported Apr 28, 2026: actual 49.94B USD, estimate 47.53B USD, surprise +5.08%, Beat. Q3 2026, reported Jul 28, 2026: actual 53.58B USD, estimate 47.64B USD, surprise +12.47%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 47.11B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$68.29

5.03% upside
Past 12 months12-month forecastHigh $80.00Average $68.29Low $39.00

CNC peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding CNC

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
978.31M
Weight
0.04%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
766.31M
Weight
0.05%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71+0.39%
iShares Core S&P 500 ETF logoiShares Core S&P 500 ETFIVV
Market value
405.39M
Weight
0.05%
AUM
891.84B USD
Expense ratio
0.03%
Price / 1D
$769.31+0.39%
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
373.7M
Weight
0.05%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72+0.41%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
353.12M
Weight
0.19%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Mid-Cap ETF logoVanguard Morningstar Mid-Cap ETFVO
Market value
332.46M
Weight
0.15%
AUM
224.7B USD
Expense ratio
0.03%
Price / 1D
$82.97+0.53%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
224.3M
Weight
0.33%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
216.44M
Weight
0.48%
AUM
44.76B USD
Expense ratio
0.08%
Price / 1D
$174.62+1.29%

Continue in GoAI

Research CNC

research.disclaimer